12:00 AM
 | 
Apr 01, 2013
 |  BioCentury  |  Finance

Betting the fat

Vivus uses IP on obesity drug Qsymia as collateral for $110M Pharmakon loan
Betting the fat

The $110 million loan Vivus Inc. (NASDAQ:VVUS) received from Pharmakon Advisors could provide the biotech with just about a year of cash to help it boost sales of obesity drug Qsymia.

Vivus launched Qsymia phentermine/topiramate last September, but sales have disappointed. The biotech reported 4Q12 revenues of $2 million. Sluggish sales have led to shareholder unrest, with First Manhattan Co. proposing its own slate of directors in March (see BioCentury, March 11).

Last week's deal with Pharmakon is...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >